A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
User plans to switch from oral to .005% topical finasteride, using a solvent from minoxidilmax and later Essengen-F. They will monitor DHT levels and seek advice on solvents and sleep caps.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
The user is considering switching their hair loss routine from taking finasteride daily to a combination of finasteride six times a week and dutasteride once a week. They are seeking advice on this potential change.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.
The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.
People are sharing their experiences with different dosages of dutasteride and finasteride for hair loss. Many report shedding initially but some see improvements over time, with some also using minoxidil.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
Finasteride, Minoxidil, a laser helmet, and ketoconazole shampoo were used to improve hair health and manage hair loss. A gentle scalp care routine is emphasized for better results.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.
The post discusses a user's hair loss treatment journey over a year, using finasteride, dutasteride (dut), and oral minoxidil (min). The user found finasteride ineffective, switched to dutasteride and oral minoxidil, and noticed improvements, but couldn't determine which of the latter two treatments was most effective.
The conversation is about whether Saw Palmetto, which has similar but less potent effects to Finasteride, could cause the same side effects due to lowering DHT levels. The user is considering oral Saw Palmetto as an alternative to Finasteride for hair loss treatment.
The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.
A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.
Combining finasteride and dutasteride may enhance hair regrowth by targeting different enzymes, with positive results reported. Minoxidil, both oral and topical, is also used to improve effectiveness.
A female with male-pattern hair loss (AGA) is seeking help after unsuccessful treatments with spironolactone and supplements, and is considering oral minoxidil and finasteride despite concerns about medication side effects. She has ruled out hormonal birth control and PRP/PRFM, and is looking into further medical advice due to abnormal lab results.
Creatine may increase DHT levels, potentially affecting hair loss, but evidence is mostly anecdotal. A study to explore this was withdrawn due to funding issues.
Creatine supplementation may increase DHT levels, potentially affecting hair loss. A study is examining this effect, with participants taking 5 grams of creatine daily for six months.
The conversation humorously discusses the journey of deciding to use finasteride for hair loss, with a focus on a funny Facebook post. It also touches on the idea of promoting finasteride use to future generations.
People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.